Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
暂无分享,去创建一个
[1] William M. Lee,et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.
[2] M. Makuuchi,et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.
[3] Xianglin L. Du,et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States , 2010, Hepatology.
[4] R. Lencioni,et al. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. , 2005, Clinics in liver disease.
[5] G. Dore,et al. Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden , 2009, Journal of viral hepatitis.
[6] H. El‐Serag,et al. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] Samir Gupta,et al. Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.
[8] R. Dhanasekaran,et al. Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation , 2012, American journal of clinical oncology.
[9] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[10] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[11] J. Bruix,et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.
[12] I. Williams,et al. Epidemiology of hepatitis C in the United States. , 1999, The American journal of medicine.
[13] Teruaki Kimura,et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis , 2004, Journal of Gastroenterology.
[14] M. Abecassis,et al. Yttrium‐90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation , 2006, Journal of surgical oncology.
[15] D. Madoff,et al. Preoperative portal vein embolization: an approach to improve the safety of major hepatic resection. , 2011, Seminars in roentgenology.
[16] M. Yamaguchi,et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: A prospective study , 1988, Hepatology.
[17] Ping Liang,et al. Microwave Ablation of Hepatocellular Carcinoma , 2007, Oncology.
[18] Jeong Min Lee,et al. Diagnostic Accuracy of Multi-/Single-Detector Row CT and Contrast-Enhanced MRI in the Detection of Hepatocellular Carcinomas Meeting the Milan Criteria before Liver Transplantation , 2008, Intervirology.
[19] K. Glaser,et al. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. , 2008, Journal of hepatology.
[20] M. Hebbar,et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma , 2008, Cancer.
[21] A. Benson,et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.
[22] H. Hussain,et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially‐enhancing liver mass , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[23] Y. Kuo,et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[24] J. Bruix,et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma , 1992, Hepatology.
[25] A. Jemal,et al. Global Cancer Statistics , 2011 .
[26] ndrea,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[27] Chien-Jen Chen,et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Chien-Jen Chen,et al. Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma , 2008, Journal of the National Cancer Institute.
[29] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[30] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[31] M. Thomas,et al. Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.
[32] M. Pompili,et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre , 2005, Gut.
[33] M. Kudo,et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma , 2011, Hepatology.
[34] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[35] J. Marrero,et al. Alpha‐fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases , 2011, Hepatology.
[36] J. Marrero,et al. Alpha-fetoprotein in early hepatocellular carcinoma. , 2010, Gastroenterology.
[37] Ching-Lung Lai,et al. Natural history of hepatitis-related hepatocellular carcinoma. , 2008, World journal of gastroenterology.
[38] M. Sherman. Serological surveillance for hepatocellular carcinoma: time to quit. , 2010, Journal of hepatology.
[39] J. Dufour,et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. , 2010, The oncologist.
[40] C. Georgiades,et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. , 2005, Journal of vascular and interventional radiology : JVIR.
[41] M. Vivarelli,et al. Liver Transplantation for Recurrent Hepatocellular Carcinoma on Cirrhosis After Liver Resection: University of Bologna Experience , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[42] T. Liang,et al. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. , 2004, Gastroenterology.
[43] Jeffrey S. Morris,et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] W. Su,et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] K. Tai,et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[46] J. Bruix,et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[47] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[48] A. Benson,et al. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[50] M. Manos,et al. Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm , 2007, Journal of viral hepatitis.
[51] J. Bruix,et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma , 2007, Hepatology.
[52] Ding‐Shinn Chen,et al. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[53] M. Ozaki,et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] H. El‐Serag,et al. Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.
[55] A. Mangia,et al. Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.
[56] A. Lim,et al. Imaging of liver cancer. , 2009, World journal of gastroenterology.
[57] V. Lee,et al. Transplantation for hepatocellular carcinoma and cirrhosis: Sensitivity of magnetic resonance imaging , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[58] T. López-Cuadrado,et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma , 2009, BMC gastroenterology.
[59] Chien-Jen Chen,et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. , 2009, Journal of the National Cancer Institute.
[60] G. Dusheiko,et al. Management of hepatocellular carcinoma. , 1992, Journal of hepatology.
[61] J. Buckels,et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis , 2008, Gut.
[62] Jae Young Lee,et al. The Value of Gadobenate Dimeglumine-Enhanced Delayed Phase MR Imaging for Characterization of Hepatocellular Nodules in the Cirrhotic Liver , 2008, Investigative radiology.
[63] Jeffrey W. Clark,et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.
[64] Katsuyoshi Ito. Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. , 2006, European journal of radiology.
[65] Akihiro Matsumoto,et al. Hepatocellular carcinoma: recent trends in Japan. , 2004, Gastroenterology.
[66] William M. Lee,et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.
[67] William M. Lee,et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.
[68] H. Yoshizawa. Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection in Japan: Projection to Other Countries in the Foreseeable Future , 2002, Oncology.
[69] Lu-Yu Hwang,et al. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.
[70] T. Davern,et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[71] M. Sherman,et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis , 2001, Gut.
[72] H. El‐Serag,et al. Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.
[73] C. Zheng,et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. , 2004, World journal of gastroenterology.
[74] J. Meyerhardt,et al. Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC). , 2010 .
[75] A. Benson,et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.
[76] B. Rubinsky,et al. Tissue Ablation with Irreversible Electroporation , 2005, Annals of Biomedical Engineering.
[77] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[78] P Boffetta,et al. A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.
[79] G. Krinsky,et al. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. , 2002, AJR. American journal of roentgenology.
[80] Mauro Salizzoni,et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.
[81] Samir Gupta,et al. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. , 2003, Annals of internal medicine.
[82] Chien-Jen Chen,et al. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B , 2009, Hepatology.
[83] K. Wakasa,et al. Hepatocellular Carcinoma Arising from Nonalcoholic Steatohepatitis: Report of Two Cases , 2005, Surgery Today.
[84] J. Bruix,et al. Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.
[85] R. Finn,et al. Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.
[86] T. George,et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma , 2011, Alimentary pharmacology & therapeutics.
[87] F. Izzo,et al. Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.
[88] Y. Tajima,et al. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation , 2009, Journal of Gastroenterology.
[89] A. Lok,et al. Does Antiviral Therapy Prevent Hepatocellular Carcinoma? , 2011, Antiviral therapy.
[90] S. Altekruse,et al. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] L. Jeng,et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. , 2009, Journal of hepatology.
[92] William M. Lee,et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.
[93] M. Taniai,et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.
[94] A. Zhu,et al. A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2010 .
[95] P. Waldenberger,et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[96] Chi-Lai Ho,et al. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[97] G. Gores,et al. Drop‐out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[98] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[99] Ramon Planas,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.
[100] S. Breitenstein,et al. “State of the Art” in Liver Resection and Living Donor Liver Transplantation: A Worldwide Survey of 100 Liver Centers , 2009, World Journal of Surgery.
[101] K. Ashizawa,et al. Complications associated with transcatheter arterial embolization for hepatic tumors. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.
[102] C. Margarit,et al. Resection of hepatocellular carcinoma in patients with cirrhosis , 1996, The British journal of surgery.
[103] R. Wiesner,et al. Results of the first year of the new liver allocation plan , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[104] J. Willatt,et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.
[105] S. Porru,et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. , 2002, American journal of epidemiology.
[106] V. Cogliano. International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.
[107] Stephanie R Wilson,et al. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. , 2006, AJR. American journal of roentgenology.
[108] M. Friedrich-Rust,et al. Tumor-Specific Vascularization Pattern of Liver Metastasis, Hepatocellular Carcinoma, Hemangioma and Focal Nodular Hyperplasia in the Differential Diagnosis of 1349 Liver Lesions in Contrast-Enhanced Ultrasound (CEUS) , 2009, Ultraschall in der Medizin.
[109] Michiie Sakamoto,et al. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.
[110] P. Philip,et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] H. Tsukuma,et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.
[112] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[113] Chang-Min Kim,et al. A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma , 2008, Journal of Nuclear Medicine.
[114] J. Bruix,et al. East meets the West—portal pressure predicts outcome of surgical resection for hepatocellular carcinoma , 2009, Nature Clinical Practice Gastroenterology &Hepatology.
[115] J. Kaldor,et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. , 2006, Journal of hepatology.
[116] Yong Hwan Jeon,et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. , 2009, AJR. American journal of roentgenology.
[117] M. Kudo,et al. Small hepatocellular carcinomas in chronic liver disease: detection with SPECT. , 1986, Radiology.
[118] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[119] R. Lencioni. Loco‐regional treatment of hepatocellular carcinoma , 2010, Hepatology.
[120] D. Geller,et al. Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation , 2008, Annals of Surgical Oncology.
[121] D. Harnois,et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .
[122] M. Ebara,et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. , 1986, Radiology.
[123] K. McGlynn,et al. The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update , 2003, Annals of Internal Medicine.
[124] Wolfgang Sadee,et al. A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas , 2009, Clinical Cancer Research.
[125] Young Kon Kim,et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. , 2006, AJR. American journal of roentgenology.
[126] Carlo Bartolozzi,et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.
[127] T. Vogl,et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.
[128] S. Pol,et al. The impact of human immunodeficiency virus on viral hepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[129] H. El‐Serag. Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.
[130] Zhao-You Tang,et al. Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.
[131] J. Groopman,et al. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[132] M. Zoli,et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) , 2002, American Journal of Gastroenterology.
[133] B. Sangro,et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. , 2008, Journal of vascular and interventional radiology : JVIR.
[134] Yun Yen,et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.
[135] M. Feitelson. Hepatitis B virus in hepatocarcinogenesis , 1999, Journal of cellular physiology.
[136] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[137] J. Marrero,et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.
[138] A. Young,et al. Needle-track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. , 2009, Gut.
[139] R. Finn,et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] D. Parkin,et al. The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.
[141] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[142] S. Fan,et al. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. , 2000, Annals of surgery.
[143] G. Casazza,et al. Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.
[144] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[145] Michael Gregor,et al. Contrast‐enhanced ultrasound with SonoVue: Differentiation between benign and malignant focal liver lesions in 317 patients , 2009, Journal of clinical ultrasound : JCU.
[146] P. Chow,et al. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians , 2011, International journal of hepatology.
[147] C. Hellerbrand,et al. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications , 2010, Gut.
[148] Carmen Ayuso,et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation , 2003, Hepatology.
[149] D. Harnois. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis , 2010 .
[150] G. Abou-Alfa,et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. , 2010, JAMA.
[151] E. Somers. International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[152] O. Matsui,et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. , 1991, Radiology.
[153] R. Poon,et al. Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge , 2011, Hepatology.
[154] Chien-Jen Chen,et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. , 2010, Gastroenterology.
[155] S. Larsson,et al. Coffee consumption and risk of liver cancer: a meta-analysis. , 2007, Gastroenterology.
[156] Ruey-min Lee,et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. , 2016, Journal of Clinical Oncology.
[157] Laura Crocetti,et al. Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US , 2007, European radiology.